BB's Stock Haven

[BottomBounce]

Big news CBD stock $INSY “Our strategic shift in focus away from opioids and to pharmaceutical-grade cannabinoids and novel drug delivery systems continues to gain momentum and has been driven by our strong commitment to advancing our diverse product pipeline,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “Through this intense focus on our reprioritized pipeline over the last year, which has been anchored by a patient-centric mission and commitment, we are radically transforming this company. As we look forward, we have the potential to submit six new drug applications over the next three years, two of which are scheduled for 2019.”